| |
| HEALTHCARE |
UAE funds Water Treatment Plant in Mosul
November 13, 2019
Al Qubba Water Treatment Plant has been inaugurated in east Mosul, in cooperation with the local government and the United Nations Development Programme (UNDP). According to the state-owned Emirates News Agency, the inauguration was attended by Mansour Marid, Governor of Mosul, and UNDP Officer of Northern Iraq Governorates Projects, who thanked the UAE for supporting the project. The"...
Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised
November 12, 2019
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whether in-hospital administration of empagliflozin 10 mg daily improves heart failure outcomes when initiated in people hospitalised for any type of acute heart failure event once they have been stabilised. The study will include participants both with and without type 2 diabetes. This"...
Mary Kay Continues Its Commitment to Advance Skin Science Research at the Japanese Society of Investigative Dermatology
November 11, 2019
As a leader in skincare innovation worldwide, Mary Kay Inc. continued its commitment to advance skin science as a symposium sponsor at the 44th annual meeting of The Japanese Society of Investigative Dermatology (JSID). At the conference held Nov. 8 - 10 in Aomori, Japan, the symposium on skin barriers and skin redness provided a collaborative environment to share technological advances and breakthroughs on skin health. Established in 1981, the"...
Male infertility is becoming a growing concern for couples looking to start a family
November 11, 2019
To raise awareness regarding matters surrounding men’s health and in observance of ‘Movember,’ an annual event involving the growing of moustaches all through the month of November, Fakih IVF Fertility Center has a special line-up of services rolled out for all its male patients. As part of the services, all male patients will be provided with a free semen analysis, with an additional 15 percent discount on all IVF-ICSI packages."...
Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation
November 10, 2019
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (Takeda) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of “switch” maintenance, the use of medicines not included in initial induction therapy, in this setting. NINLARO is currently not approved for this specific use. “We are very encouraged by the results of the TOURMALINE-MM4 trial and continue our forward momentum in developing maintenance options for multiple myeloma patients. Importantly, this is the third positive Phase 3 readout......
New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period
November 8, 2019
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO® (lanadelumab-flyo) injection in patients with hereditary angioedema (HAE) 12 years of age and older studied in the ongoing Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE). The analyses, being presented at the 2019 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting in Houston, Texas from November 7-11, showed that TAKHZYRO continued to prevent HAE attacks at a rate similar to that observed in the pivotal HELP Study, in patients who received treatment for a mean duration of 19.7 (0-26.1) months.1, 2 The analyses will also be published in the November issue of ACAAI’s journal Annals of Allergy, Asthma & Immunology. The original Phase......
Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure
November 7, 2019
− New England Journal of Medicine publishes primary endpoint analysis from ongoing Phase 3 study of Takeda’s dengue vaccine candidate
− Over 20,000 study participants in dengue-endemic areas in Latin America and Asia received two doses of Takeda’s dengue vaccine candidate or placebo administered three months apart
− Results demonstrated overall vaccine efficacy of 80.2% (12-month follow-up after second dose) against virologically confirmed dengue; exploratory analyses"...
Fakih IVF Oman celebrates 49th Oman National Day
November 7, 2019
Fakih IVF Fertility Center in Oman has recently witnessed an increase in number of patients battling infertility, over 800 patients have been treated since its inception. Doctors at the center suggest that the inability to conceive in certain cases is due to female factors and in many others is due to a man being infertile. Therefore on the occasion of the 49th Oman National Day, Fakih IVF is providing all patients the opportunity to benefit from"...
Takeda Unveils New Dengue Vaccine Manufacturing Plant in Germany
November 7, 2019
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003. The Singen vaccine plant will be utilized for formulation, fill, finish and secondary packaging of the dengue vaccine candidate starting with the packaging line. Takeda invested more than 130 million Euro and will employ up to 200 employees in the vaccine plant. According to the World Health Organization (WHO), dengue is the fastest spreading mosquito-borne viral disease, which is estimated to cause approximately 390 million infections and 20,000 deaths globally each year.2 “This project is one of our most significant investments within our global manufacturing network. We are proud to open this new, state of the art sterile manufacturing plant, which combines a high degree of automation......
Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates
November 6, 2019
- Agreement with Biogen covers Samsung Bioepis’ biosimilar candidates in pre-clinical and clinical development, which reference two widely-used biologic medicines in ophthalmology: ranibizumab and aflibercept
- Includes an option for Biogen to extend existing commercialization agreement for Samsung Bioepis’ anti-TNF medicines in Europe – BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) – which have treated over 180,000 patients across Europei
- Samsung Bioepis continues its commitment to increasing patient...
|
|
|
|
|